Article

Designer Oncolytic Adenovirus: Coming of Age

2018-06-15

Abstract excerpt

The licensing of talimogene laherparepvec (T-Vec) represented a landmark moment for oncolytic virotherapy, since it provided unequivocal evidence for the long-touted potential of genetically modified replicating viruses as anti-cancer agents. Whilst T-Vec is promising as a locally delivered virotherapy, especially in combination with immune-checkpoint inhibitors, the quest continues for a virus capable of specific...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 60f5d739-1713-5070-847f-baa18563ba67
DOI: 10.20944/preprints201805.0273.v2

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Designer Oncolytic Adenovirus: Coming of AgeDOI 10.20944/preprints201805.0273.v2Read

Oncolytic viruses: programmable tumour hunters.Semantic proximity Read

Oncolytic adenovirus: A tool for cancer therapy in combination with other therapeutic approachesSemantic proximity Read

Evolving Horizons: Adenovirus Vectors’ Timeless Influence on Cancer, Gene Therapy and VaccinesSemantic proximity Read

Replicative Oncolytic Adenoviruses in Multimodal Cancer RegimensSemantic proximity Read

Oncolytic viruses: finally deliveringSemantic proximity Read

Designing herpes viruses as oncolyticsSemantic proximity Read

Designing adenoviral vectors for tumor-specific targeting.Semantic proximity Read

Oncolytic adenoviruses – selective retargeting to tumor cellsSemantic proximity Read

Retargeting adenoviruses for therapeutic applications and vaccinesSemantic proximity Read

Virotherapy: cancer gene therapy at last?Semantic proximity Read

Armed replicating adenoviruses for cancer virotherapySemantic proximity Read

Cellular genetic tools to control oncolytic adenoviruses for virotherapy of cancerSemantic proximity Read